Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Receivables - Net (2018 - 2025)

Historic Receivables - Net for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to $1.9 million.

  • Denali Therapeutics' Receivables - Net rose 3571.43% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 3571.43%. This contributed to the annual value of $1.5 million for FY2024, which is 5614.04% down from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Receivables - Net is $1.9 million, which was up 3571.43% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Receivables - Net peaked at $15.2 million during Q2 2021, and registered a low of $1.4 million during Q2 2024.
  • Moreover, its 5-year median value for Receivables - Net was $1.9 million (2024), whereas its average is $3.7 million.
  • In the last 5 years, Denali Therapeutics' Receivables - Net skyrocketed by 497266.67% in 2021 and then tumbled by 6315.45% in 2023.
  • Denali Therapeutics' Receivables - Net (Quarter) stood at $15.2 million in 2021, then plummeted by 39.01% to $9.3 million in 2022, then crashed by 63.15% to $3.4 million in 2023, then tumbled by 56.14% to $1.5 million in 2024, then increased by 26.67% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.4 million for Q2 2025, and $1.7 million during Q1 2025.